GTx Announces Panel Discussion at Citi’s 6th Annual Biotech Day

MEMPHIS, Tenn.--(BUSINESS WIRE)-- GTx, Inc. (NASDAQ: GTXI) announced today that Dr. Mitchell S. Steiner, CEO, is scheduled to participate in a panel discussion on the topic “Finally, Lots of Options for Treating Prostate Cancer ” at Citi’s 6th Annual Biotech Day on Wednesday, September 7, 2011, at 11:00 a.m. ET. The conference will be held at the Ritz Carlton hotel in Boston, Massachusetts.

About GTx

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways for the treatment of cancer, cancer supportive care, and other serious medical conditions.



CONTACT:

GTx, Inc.
McDavid Stilwell, 901-523-9700
Director, Corporate Communications & Financial Analysis

KEYWORDS:   United States  North America  Massachusetts  Tennessee

INDUSTRY KEYWORDS:   Health  Biotechnology  Consumer  General Health  Men

MEDIA:

Logo
 Logo

Suggested Articles

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.

AbbVie and Roche alum Janet Hammond, M.D., Ph.D., Sc.M., F.C.P. has nabbed the chief development officer role at infectious disease biotech Atea.